Video

Dr. Waks on the Continued Evaluation of Immunotherapy in HER2+ Breast Cancer

Adrienne G. Waks, MD, discusses the continued evaluation of immunotherapy in HER2-positive breast cancer.

Adrienne G. Waks, MD, physician, associate director of Clinical Research, Dana-Farber Cancer Institute, instructor in Medicine, Harvard Medical School, discusses the continued evaluation of immunotherapy in HER2-positive breast cancer.

Recently published data from the phase 3 IMpassion050 trial (NCT03726879) showed that atezolizumab (Tecentriq) did not add any benefit to pathological complete response rates when added to the standard-of-care regimen of 4 cycles of dose-dense doxorubicin and cyclophosphamide, followed by paclitaxel plus pertuzumab (Perjeta) and trastuzumab (Herceptin) in combination, Waks explains. Moreover, these data were similar all for patients, including those in the intent-to-treat and PD-L1–positive populations, Waks says.

The phase 2 KATE2 trial (NCT02924883) is evaluating ado-trastuzumab emtansine (T-DM1; Kadcyla) in combination with atezolizumab in the metastatic setting, based on previous suggestive data that implied there may benefit to adding a checkpoint blockade for the PD-L1–positive subset of patients, Waks continues. Though data from KATE2 have not been read out, it is uncertain what role immune checkpoint blockade could have in HER2-positive breast cancer in the early and the later stage settings, Waks concludes.

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD